Top Abstracts with Expert Perspective: Lymphoma
Tracks
Track 3
| Monday, April 29, 2024 |
| 8:00 AM - 9:30 AM |
| Room 3A |
Speaker
Dr William Townsend
Consultant Haematologist
University College London Hospitals
Fixed-Duration Glofitamab Monotherapy in Relapsed/Refractory Large B-Cell Lymphoma: Phase II Extended Follow-Up and Subgroup Analyses
8:00 AM - 8:15 AM
Dr Kushani Ediriwickrema
Lymphoma Clinical Fellow
University College Hospital London
Glofitamab Efficacy, Tolerability, and Practical Implications in the Real World: A UK Multicentre, Retrospective Analysis.
8:15 AM - 8:30 AM
Dr William Townsend
Consultant Haematologist
University College London Hospitals
Glofitamab Plus R-CHOP or Pola-R-CHP in 1L Diffuse Large B-Cell Lymphoma: a Phase Ib Study
8:30 AM - 8:45 AM
Dr Kim M. Linton
Clinical Senior Lecturer In Medical Oncology
Manchester Cancer Research Centre
Epcoritamab Monotherapy Leads to Deep and Durable Responses in R/R FL: Pivotal EPCORE NHL-1 Data
Dr Anna Crawford
Registrar
University College London Hospitals
Brentuximab Vedotin and Bendamustine for relapsed Hodgkin Lymphoma: high CR rate and manageable toxicity
9:00 AM - 9:15 AM
Prof. Graham Collins
Consultant Haematologist
Oxford University Hospitals NHS Foundation Trust
ANIMATE: A UK Phase II PET Response-Adapted Trial of Nivolumab in Relapsed Classical Hodgkin Lymphoma
9:15 AM - 9:30 AMChair
Sridhar Chaganti
Co Chair
Cathy Burton
Consultant Haematologist
Leeds Teaching Hospitals NHS Trust
